Last month we discussed that Axsome Therapeutics stock is likely to continue to see higher levels after it rose 6% in a week following the U.S. FDA's acceptance of a new drug application for the company's migraine drug - AXS-07. AXSM stock has since then rallied 27% to levels of nearly $38 now...
Last month we discussed that Axsome Therapeutics stock is likely to continue to see higher levels after it rose 6% in a week following the U.S. FDA's acceptance of a new drug application for the company's migraine drug - AXS-07. AXSM stock has since then rallied 27% to levels of nearly $38 now...
Share this Article
Recommended